SCHEMBL3066580

SCHEMBL3066580

CC(C)(C)C(=O)Nc1cnc(-c2ccncc2Cl)c(-c2cccnc2)n1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 8/20 0.72
CYP3A4 P08684 6/20 0.56
CYP2C19 P33261 6/20 0.56
CYP1A2 P05177 5/20 0.56
CYP2C9 P11712 4/20 0.56
ADORA2A P29274 5/20 0.52
ADORA1 P30542 2/20 0.40
CYP2D6 P10635 3/20 0.40
ALDH1A1 P00352 2/20 0.40
POLB P06746 2/20 0.40
KMT2A Q03164 2/20 0.39
PPARG P37231 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NR2E3 Q9Y5X4 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3075704 0.84 ADORA2B (1.00) ADORA2BCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL3066499 0.76 ADORA2B (0.75) ADORA2BCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL3063962 0.74 ADORA2B (0.57) ADORA2BCYP3A4CYP2C19CYP2C9ADORA2A
SCHEMBL3064609 0.73 ADORA2B (0.82) ADORA2BCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL3063903 0.73 ADORA2B (0.71) ADORA2BCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL3064248 0.73 ADORA2B (0.71) ADORA2BCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL3074836 0.73 ADORA2B (0.74) ADORA2BCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL3063823 0.72 ADORA2B (0.68) ADORA2BCYP3A4CYP2C19CYP1A2CYP2C9
Las101057 SCHEMBL29941566 0.71 ADORA2B (1.00) ADORA2BCYP3A4CYP2C19CYP1A2CYP2C9
Las101057 SCHEMBL3075657 0.71 ADORA2B (1.00) ADORA2BCYP3A4CYP2C19CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US claimed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US claimed
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US disclosed
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US disclosed
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US disclosed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US disclosed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US disclosed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US disclosed
WO-2007017096-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. (ES) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists ADORA2B, ADORA2A, ADORA3 ADORA2B 1/4885CYP3A4 1868/4885CYP2C19 1218/4885
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS ADORA2B, ADORA2A, ADORA1 ADORA2B 1/4885CYP3A4 857/4885CYP2C19 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.